Long-Standing Enigma Finally Cracked – Link Discovered Between High Blood Pressure and Diabetes
उच्च रक्तचाप (उच्च रक्तचाप के रूप में जाना जाता है) से पीड़ित इतने सारे रोगियों को मधुमेह (उच्च रक्त शर्करा) क्यों है, इसकी लंबे समय से चली आ रही पहेली को आखिरकार ब्रिस्टल, यूके और ऑकलैंड, न्यूजीलैंड के विश्वविद्यालयों के नेतृत्व में एक अंतरराष्ट्रीय टीम ने सुलझा लिया है। .
महत्वपूर्ण नई खोज से पता चला है कि एक छोटा प्रोटीन सेल ग्लूकागन जैसा पेप्टाइड -1 (जीएलपी -1) शरीर के रक्त शर्करा के नियंत्रण को जोड़ता है तथा रक्त चाप।
प्रोफेसर जूलियन पैटन, एक वरिष्ठ लेखक, और मनाकी मोनावा के निदेशक - ऑकलैंड विश्वविद्यालय में सेंटर फॉर हार्ट रिसर्च ने कहा: “हम लंबे समय से जानते हैं कि उच्च रक्तचाप और मधुमेह का अटूट संबंध है और आखिरकार इसका कारण खोज लिया है, जो अब नई उपचार रणनीतियों की जानकारी देगा।”
शोध, प्रिंट से पहले ऑनलाइन प्रकाशित हुआ परिसंचरण अनुसंधान 1 फरवरी, 2022 को, ब्राजील, जर्मनी, लिथुआनिया और सर्बिया के साथ-साथ यूके और न्यूजीलैंड में सहयोगी वैज्ञानिकों का योगदान शामिल था।
जीएलपी -1 खाने के बाद आंत की दीवार से निकलता है और रक्त शर्करा के स्तर को नियंत्रित करने के लिए अग्न्याशय से इंसुलिन को उत्तेजित करने का काम करता है। यह ज्ञात था लेकिन अब जो पता चला है वह यह है कि जीएलपी -1 गले में स्थित कैरोटिड बॉडी नामक एक छोटे से संवेदी अंग को भी उत्तेजित करता है।
[{” attribute=””>University of Bristol group used an unbiased, high-throughput genomics technique called RNA
” data-gt-translate-attributes=”[{” attribute=””>RNA sequencing to read all the messages of the expressed genes in the carotid body in rats with and without high blood pressure. This led to the finding that the receptor that senses GLP-1 is located in the carotid body, but less so in hypertensive rats.
David Murphy, Professor of Experimental Medicine from Bristol Medical School: Translational Health Sciences (THS) and senior author, explained: “Locating the link required genetic profiling and multiple steps of validation. We never expected to see GLP-1 come up on the radar, so this is very exciting and opens many new opportunities.”
Professor Paton added: “The carotid body is the convergent point where GLP-1 acts to control both blood sugar and blood pressure simultaneously; this is coordinated by the nervous system which is instructed by the carotid body.”
People with hypertension and/or diabetes are at high risk of life-threatening cardiovascular disease. Even when receiving medication, a large number of patients will remain at high risk. This is because most medications only treat symptoms and not causes of high blood pressure and high sugar.
Professor Rod Jackson, world-renowned epidemiologist from the University of Auckland, said “We’ve known that blood pressure is notoriously difficult to control in patients with high blood sugar, so these findings are really important because by giving GLP-1 we might be able to reduce both sugar and pressure together, and these two factors are major contributors to cardiovascular risk.”
Mr. Audrys Pauža, a British Heart Foundation-funded PhD student in Professor David Murphy’s lab in the Bristol Medical School and lead author on the study, added: “The prevalence of diabetes and hypertension is increasing throughout the world, and there is an urgent need to address this.
“Drugs targeting the GLP-1 receptor are already approved for use in humans and widely used to treat diabetes. Besides helping to lower blood sugar these drugs also reduce blood pressure, however, the mechanism of this effect wasn’t well understood.
“This research revealed that these drugs may actually work on the carotid bodies to enact their anti-hypertensive effect. Leading from this work, we are already planning translational studies in humans to bring this discover into practice so that patients most at risk can receive the best treatment available.”
But GLP-1 is just the start. The research has revealed many novel targets for ongoing functional studies that the team anticipate will lead to future translational projects in human hypertensive and diabetic patients.
Reference: “GLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition” by Audrys G. Pauza, Pratik Thakkar, Tatjana Tasic, Igor Felippe, Paul Bishop, Michael P. Greenwood, Kristina Rysevaite-Kyguoliene, Julia Ast, Johannes Broichhagen, David J. Hodson, Helio C. Salgado, Dainius H. Pauza, Nina Japundzic-Zigon, Julian F.R. Paton and David Murphy, 1 February 2022, Circulation Research.
DOI: 10.1161/CIRCRESAHA.121.319874
The study was funded by the British Heart Foundation and the Health Research Council of New Zealand.
(function(d, s, id){
var js, fjs = d.getElementsByTagName(s)[0]; अगर (d.getElementById(id)) वापसी; js = d.createElement(s); जेएस आईडी = आईडी; js.src = “//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.6”; fjs.parentNode.insertBefore(js, fjs); }(दस्तावेज़, ‘स्क्रिप्ट’, ‘facebook-jssdk’));
